View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2014	Mar. 02, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	HERON THERAPEUTICS, INC. /DE/
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		29,531,197
Entity Public Float			$ 162,634,000
Amendment Flag	false
Entity Central Index Key	0000818033
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 72,675	$ 72,287
Prepaid expenses and other current assets	1,057	638
Total current assets	73,732	72,925
Property and equipment, net	2,820	2,882
Other assets	130	130
Total assets	76,682	75,937
Current liabilities:
Accounts payable	2,549	1,264
Accrued clinical liabilities	3,811	1,773
Accrued payroll and employee liabilities	2,731	2,566
Other accrued liabilities	2,931	364
Convertible notes payable to related parties, net of discount	1,598	1,025
Total current liabilities	13,620	6,992
Stockholders’ equity:
Preferred stock, $0.01 par value: 2,500 shares authorized; no shares issued or outstanding at December 31, 2014 and 2013	0	0
Common stock, $0.01 par value: 75,000 shares authorized; 29,227 and 23,572 shares issued and outstanding at December 31, 2014 and 2013, respectively	292	237
Additional paid-in capital	378,007	307,578
Accumulated deficit	(315,237)	(238,870)
Total stockholders’ equity	63,062	68,945
Total liabilities and stockholders’ equity	$ 76,682	$ 75,937

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,500,000	2,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	29,227,000	23,572,000
Common stock, shares outstanding	29,227,000	23,572,000

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating expenses:
Research and development	$ 54,833	$ 32,516	$ 15,174
General and administrative	19,728	21,941	8,657
Total operating expenses	74,561	54,457	23,831
Loss from operations	(74,561)	(54,457)	(23,831)
Other income (expense):
Interest expense	(887)	(828)	(605)
Other income (expense), net	(919)	2	6
Total other income (expense)	(1,806)	(826)	(599)
Loss from continuing operations	(76,367)	(55,283)	(24,430)
Gain from discontinued operations			1,082
Net loss	$ (76,367)	$ (55,283)	$ (23,348)
Basic and diluted net loss per share:
Loss from continuing operations (in Dollars per share)	$ (2.87)	$ (3.42)	$ (2.00)
Net loss (in Dollars per share)	$ (2.87)	$ (3.42)	$ (1.91)
Shares used in computing basic and diluted net loss per share (in Shares)	26,569	16,163	12,223

Statements of Stockholders' Equity - USD ($) $ in Thousands	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Note Warrant [Member] Common Stock [Member]	Note Warrant [Member] Additional Paid-in Capital [Member]	Note Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2011							$ 100	$ 175,891	$ (160,239)	$ 15,752
Balance (in Shares) at Dec. 31, 2011							10,002,000
Issuance of stock, value	$ 51	$ 50,440	$ 50,491	$ 1	$ (1)
Issuance of stock, shares (in Shares)	5,100,000			5,000
Stock-based compensation expense								5,552		5,552
Fair value of warrants issued to non-employees								180		180
Net loss									(23,348)	(23,348)
Conversion benefit included in Convertible Notes issued								3,169		3,169
Issuance of common stock under Employee Stock Purchase Plan								22		$ 22
Issuance of common stock under Employee Stock Purchase Plan (in Shares)							4,000
Issuance of common stock upon exercise of stock options (in Shares)										0
Balance at Dec. 31, 2012							$ 152	235,253	(183,587)	$ 51,818
Balance (in Shares) at Dec. 31, 2012							15,111,000
Issuance of stock, value				$ 2	598	$ 600
Issuance of stock, shares (in Shares)				212,000
Stock-based compensation expense								10,890		10,890
Net loss									(55,283)	(55,283)
Issuance of common stock in a public offering, net							$ 77	57,725		57,802
Issuance of common stock in a public offering, net (in Shares)							7,706,000
Conversion benefit included in Convertible Notes issued								291		291
Issuance of common stock under Employee Stock Purchase Plan							$ 1	33		34
Issuance of common stock under Employee Stock Purchase Plan (in Shares)							6,000
Issuance of common stock upon exercise of stock options							$ 5	2,788		$ 2,793
Issuance of common stock upon exercise of stock options (in Shares)							537,000			537,029
Balance at Dec. 31, 2013							$ 237	307,578	(238,870)	$ 68,945
Balance (in Shares) at Dec. 31, 2013							23,572,000
Issuance of stock, value				$ 3	$ (3)
Issuance of stock, shares (in Shares)				304,000
Stock-based compensation expense								8,067		8,067
Net loss									(76,367)	(76,367)
Issuance of common stock and pre-funded warrants in a public offering, net							$ 47	58,869		58,916
Issuance of common stock and pre-funded warrants in a public offering, net (in Shares)							4,751,000
Conversion benefit included in Convertible Notes issued								309		309
Issuance of common stock under Employee Stock Purchase Plan								91		91
Issuance of common stock under Employee Stock Purchase Plan (in Shares)							12,000
Issuance of common stock upon exercise of stock options							$ 5	3,096		$ 3,101
Issuance of common stock upon exercise of stock options (in Shares)							588,000			756,593
Balance at Dec. 31, 2014							$ 292	$ 378,007	$ (315,237)	$ 63,062
Balance (in Shares) at Dec. 31, 2014							29,227,000

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities:
Net loss	$ (76,367,000)	$ (55,283,000)	$ (23,348,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Stock-based compensation	8,067,000	10,890,000	5,732,000
Depreciation and amortization	578,000	333,000	197,000
Amortization of debt discount	573,000	533,000	389,000
Gain from discontinued operations			(1,082,000)
Impairment loss on property and equipment	905,000
Loss on disposal of property and equipment	17,000
Change in operating assets and liabilities:
Prepaid expense and other current assets	(419,000)	(54,000)	(318,000)
Accounts payable	1,285,000	(426,000)	984,000
Accrued clinical liabilities	2,038,000	1,127,000	92,000
Accrued payroll and employee liabilities	165,000	2,153,000	(149,000)
Other accrued liabilities	2,876,000	(36,000)	494,000
Net cash used for operating activities	(60,282,000)	(40,763,000)	(17,009,000)
Investing activities:
Purchases of property and equipment	(1,438,000)	(1,685,000)	(972,000)
Net cash used for investing activities	(1,438,000)	(1,685,000)	(972,000)
Financing activities:
Net proceeds from sale of common stock and/or pre-funded warrants	58,916,000	57,802,000	50,491,000
Proceeds from purchases under the Employee Stock Purchase Plan	91,000	34,000	22,000
Proceeds from stock option exercises	3,101,000	2,793,000
Proceeds from warrant exercises		600,000
Net proceeds from convertible note financing			3,000,000
Net cash provided by financing activities	62,108,000	61,229,000	53,513,000
Net increase in cash and cash equivalents	388,000	18,781,000	35,532,000
Cash and cash equivalents at beginning of year	72,287,000	53,506,000	17,974,000
Cash and cash equivalents at end of year	72,675,000	72,287,000	53,506,000
Supplemental disclosure of cash flow information:
Interest paid	$ 0	$ 0	$ 0

Note 1 - Organization and Business

12 Months Ended

Dec. 31, 2014

Disclosure Text Block [Abstract]

Business Description and Basis of Presentation [Text Block]

1.	Organization and Business

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. Our product development efforts focus on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effect or duration of action, or eliminate the drawbacks of current therapies. Our proprietary Biochronomer polymer-based drug delivery platform technology is designed to improve the therapeutic profile of injectable pharmaceuticals. We continue to evaluate other development programs, technologies or product candidates that may be complementary to or synergistic with our existing programs and product development goals.

Our Biochronomer technology, with which SUSTOL and certain of our other product candidates are formulated, consists of bioerodible polymers designed to release drugs over a defined period of time, depending on the medical need of a given therapeutic target. We have demonstrated that our Biochronomer technology can deliver drugs over periods varying from days to weeks and that the technology is potentially applicable to a range of therapeutic areas, including the prevention of chemotherapy-induced nausea and vomiting (“CINV”) and pain management, among others. Furthermore, we have completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymer is well tolerated. Our lead product candidate, SUSTOL, is in development for the prevention of CINV following administration of chemotherapeutic agents. Our development programs include HTX-011 for the management of post-operative pain, HTX-019 for the prevention of CINV and HTX-003 for management of chronic pain and opioid addiction.

Our lead investigational product candidate, APF530, which we intend to market as SUSTOL (granisetron injection, extended release), subject to regulatory approval, is being developed for the prevention of both acute- and delayed-onset CINV. The 5-hydroxytryptamine type 3 (“5-HT3”) receptor antagonist granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy. Injectable and oral formulations of granisetron are currently approved, but are only for the treatment of acute-onset CINV. SUSTOL is formulated utilizing our proprietary Biochronomer technology and has been shown in clinical studies to maintain therapeutic drug levels of granisetron for up to five days with a single subcutaneous injection. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed-onset CINV following the administration of highly emetogenic agents (“HEC study”), which, if successful, would differentiate SUSTOL from the other 5-HT3 receptor antagonists that are currently approved. We anticipate completing enrollment of our HEC study at the end of the first quarter of 2015.

In May 2009, we filed a New Drug Application (“NDA”) for SUSTOL with the U.S Food and Drug Administration (“FDA”) under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In March 2010, we received our first Complete Response Letter (“CRL”), which stated that the May 2009 NDA requesting approval of SUSTOL, could not be approved as it was initially submitted. The primary points raised in the initial CRL were related to the dosing system, certain identified deficiencies in the chemistry, manufacturing, and control (“CMC”) review, and the request we perform additional studies showing bioequivalence and metabolic rates and on human factors, and to perform a QT study. We met with the FDA in 2011 to clarify the comments and requests and subsequently performed additional work and data analyses which we believed addressed the concerns raised in the 2010 CRL. In September 2012, we resubmitted the NDA seeking approval for SUSTOL and in March 2013, the FDA issued a second CRL. The FDA identified several additional issues precluding the approval of the SUSTOL NDA resubmission, including further issues relating to the CMC review and deficiencies at certain of our contract manufacturers, and requested that we repeat human factors testing using commercially equivalent material, as well to provide data to allow reanalysis of our Phase 3 clinical results under the revised ASCO 2011 CINV guidelines. We believe that we have substantially addressed the issues raised in the March 2013 CRL, which will be reflected in our upcoming resubmission. We intend to include the results of our ongoing HEC study in the resubmission of our NDA for SUSTOL, which we anticipate filing mid-year 2015.

In November 2013, we initiated a development program targeting pain management. In recent years, the FDA has focused on approving drugs to successfully treat post-surgical pain, to reduce reliance on opioids, which can lead to post-surgical complications, extended hospitalization, as well as abuse and addiction. We believe there is significant opportunity for a non-opioid, sustained-release product targeting the post-surgical pain market. Our lead product candidate for this program is HTX-011, a combination of the local anesthetic bupivacaine and the anti-inflammatory meloxicam formulated utilizing our proprietary Biochronomer technology to release drug for up to 72 hours. We intend to evaluate this product in soft-tissue, nerve block, and orthopedic post-surgical settings. In the first quarter of 2015, we initiated a Phase 1 study to evaluate the safety of HTX-011 in healthy volunteers. Following the completion of the ongoing Phase 1 study, we plan to initiate additional Phase 1b/2 studies in 2015.

In November 2014, we announced our development program for HTX-019. HTX-019 is a proprietary injectable formulation of aprepitant, a neurokinin-1 (“NK1”) receptor antagonist used in combination with 5-HT3 receptor antagonists for the prevention of CINV. The HTX-019 formulation is distinguishable from the only injectable NK1 receptor antagonist approved in the U.S. for the prevention of CINV, in that it does not contain polysorbate 80, which may cause hypersensitivity or other adverse reactions in some patients. We believe there is an unmet need for expanded options for NK1 receptor antagonists, particularly those which may potentially reduce the risk of complications from hypersensitivity reactions. Subject to discussion with the FDA, we plan to develop HTX-019 utilizing the 505(b)(2) registration pathway.

In December 2014, we disclosed a second investigational product in our pain management program. HTX-003 is a long-acting formulation of buprenorphine for the treatment of chronic pain and opioid addiction. HTX-003 is formulated with our Biochronomer technology to deliver drug over 30 days with a single subcutaneous injection and accordingly is expected to have a low potential for patient abuse. We are presently evaluating our plans for further development for this product.

In January 2014, we changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. Effective January 13, 2014, we effected a 1-for-20 reverse split of our outstanding common stock (“Reverse Stock Split”) (See Note 7).

Liquidity

We have incurred significant operating losses and negative cash flows from operations and we have an accumulated deficit of $315.2 million as of December 31, 2014. Since 2011, we completed a total of five rounds of equity and/or convertible debt financings, which provided us with cash of approximately $194.3 million, net of issuance costs, to fund operations (see Notes 5 and 6). As of December 31, 2014, we had cash and cash equivalents on hand of $72.7 million.

We believe that our current working capital is sufficient to fund operations through 2015, including pursuing regulatory approval to market SUSTOL, and completing Phase 1 human clinical studies commenced in 2015 relative to our HTX-011 and HTX-019 development programs and related preclinical activities. In the event we were to pursue clinical product development in other areas, potentially acquire other strategic assets, or begin to make significant investments in preparing for commercialization of SUSTOL, we would need to raise additional capital. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. Our capital requirements going forward will depend on numerous factors, including: the scope, rate of progress, results and costs of preclinical testing and clinical trials, including completing our HEC Study; an approval decision by the FDA with respect to SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of SUSTOL; the number and characteristics of product development programs we pursue and the pace of each program including the timing of clinical trials; the time, cost and outcome involved in seeking other regulatory approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution capabilities if we commercialize products independently; the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions.

We may not be able to raise sufficient additional capital when we need it on favorable terms, or at all. The sale of additional equity in the future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on unattractive terms.

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.

Reclassifications

Certain amounts in the 2013 financial statements have been reclassified to conform to the 2014 presentation.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (“Convertible Notes”).

Fair Value of Financial Instruments

Financial instruments, including cash and cash equivalents, receivables, prepaid expenses, other current assets, accounts payable and accrued expenses, are carried at cost, which is considered to be representative of their respective fair values because of the short-term maturity of these instruments. Our Convertible Notes outstanding at December 31, 2014 do not have a readily available ascertainable market value, however, the carrying value is considered to approximate its fair value (see Note 3 for further details regarding the fair value of financial instruments).

Concentration of Credit Risk

Cash and cash equivalents are financial instruments which potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may be in excess of insured limits. We may also invest our excess cash in money market funds, certificates of deposit or United States government and agency obligations. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (primarily five years). Leasehold improvements are stated at cost and amortized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.

Impairment of Long-Lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and records the impairment as a reduction in the carrying value of the related asset with a corresponding charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment and assumptions that could differ materially from actual results.

Accrued Clinical Liabilities

We review and accrue clinical costs based on work performed, which relies on estimates of the progress of the trials and the related expenses incurred. Clinical trial related contracts vary significantly in duration, and may be for a fixed amount, based on the achievement of certain contingent events or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or contain a combination of these elements. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development costs, however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations.

Research and Development Expenses

All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation, fees paid to outside service providers and consultants, facilities costs and materials used in the clinical and preclinical trials and research and development.

Patent Costs

We incur fees of outside legal counsel in connection with filing and maintaining its various patent applications. All patent costs are expensed as incurred and included in general and administrative expense in the Statements of Operations.

Stock-Based Compensation Expense

We estimate the fair value of stock-based payment awards using the Black-Scholes option pricing model. This fair value is then amortized using the straight-line single-option method of attributing the value of stock-based compensation to expense over the requisite service periods of the awards. The Black-Scholes option pricing model requires the input of highly complex and subjective assumptions, including each option’s expected life and price volatility of the underlying stock.

As stock-based compensation expense is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on historical experience.

Warrants

We have issued warrants to purchase shares of our common stock in conjunction with certain equity financings. The terms of the warrants were evaluated to determine the appropriate classification as equity or a liability.

Income Taxes

Accounting Standard Codification No. 740, Accounting for Uncertainty in Income Taxes, clarifies the accounting for uncertain tax positions. This provision requires that we recognize the impact of a tax position in our financial statements if the position is more likely than not to be sustained upon examination and on the technical merits of the position. The total amount of unrecognized tax benefits as of December 31, 2014 was $120,000 which, if recognized, would affect other tax accounts, primarily deferred taxes in future periods, and would not affect our effective tax rate since we maintain a full valuation allowance against its deferred tax assets (see Note 8 for further details).

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for all periods presented was comprised solely of our net loss and there were no other changes in equity from non-owner sources.

Earnings per Share

Basic earnings per share (“EPS”) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.

Because we have incurred a net loss for all periods presented in the statements of operations, outstanding stock options, warrants and common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive.

The following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands):

	As of December 31,
	2014		2013		2012

Stock options outstanding		7,918		6,356		4,324
Warrants outstanding		4,108		3,969		4,219
Common stock underlying Convertible Notes outstanding		6,677		6,291		5,927

Recent Accounting Pronouncements

In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-01, Income Statement—Extraordinary and Unusual Items (Subtopic 225-20) (“ASU 2015-01”). ASU 2015-01 eliminates the concept of extraordinary items from GAAP. ASU 2015-01 will save time and reduce costs for preparers because they will not have to assess whether a particular event or transaction event is extraordinary (even if they ultimately would conclude it is not). This also alleviates uncertainty for preparers, auditors, and regulators because auditors and regulators no longer will need to evaluate whether a preparer treated an unusual and/or infrequent item appropriately. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring. The amendments in ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We plan to adopt the provisions on ASU 2015-01 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.

In August 2014, FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40) (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial satements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions on ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.

In June 2014, FASB issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718) (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. We adopted this guidance in 2014 and it did not have a material impact on our financial condition, results of operations or related financial statement disclosures.

Note 3 - Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3.	Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, is as follows:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A company may elect to use fair value to measure accounts and loans receivable, available-for-sale and held-to-maturity securities, equity method investments, accounts payable, guarantees and issued debt. Other eligible items include firm commitments for financial instruments that otherwise would not be recognized at inception and non-cash warranty obligations where a warrantor is permitted to pay a third party to provide the warranty goods or services. If the use of fair value is elected, any upfront costs and fees related to the item such as debt issuance costs must be recognized in earnings and cannot be deferred. The fair value election is irrevocable and generally made on an instrument-by-instrument basis, even if a company has similar instruments that it elects not to measure based on fair value. Unrealized gains and losses on existing items for which fair value has been elected are reported as a cumulative adjustment to beginning retained earnings and any changes in fair value are recognized in earnings. We have not elected not to apply the fair value option to our financial assets and liabilities.

We consider the carrying amount of cash and cash equivalents, receivables, prepaid expenses and other current assets, accounts payable and accrued liabilities to be representative of their respective fair values because of the short-term nature of those instruments. For the year ended December 31, 2014, we did not hold any investment securities and our cash equivalents consisted of money market funds. We did not hold any cash equivalents or investment securities during the year ended December 31, 2013.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Balance Sheet Details

12 Months Ended

Dec. 31, 2014

Disclosure Text Block Supplement [Abstract]

Supplemental Balance Sheet Disclosures [Text Block]

4.	Balance Sheet Details

Property and Equipment

Property and equipment is comprised of the following (in thousands):

	December 31,
	2014			2013
Scientific equipment	$	4,793		$	4,371
Computer equipment and software		1,133			1,080
Furniture, fixtures and office equipment		351			344
Leasehold improvements		1,376			1,360
		7,653			7,155
Less: accumulated depreciation and amortization		(4,833	)		(4,273	)
	$	2,820		$	2,882

Depreciation and amortization expense for the years ended December 31, 2014, 2013 and 2012 was approximately $578,000, $333,000 and $197,000, respectively.

During the year ended December 31, 2014, we recognized $905,000 as an impairment loss due to the write-down of a piece of manufacturing-related equipment. In March 2013, we received a CRL from the FDA which included issues to address related to our manufacturing process. As such, we made changes to our supply chain which in turn made this piece of manufacturing-related equipment no longer of use. As of December 31, 2014, the estimated fair value of the equipment was approximately $115,000 which was based on our experience with the resale of used manufacturing equipment and the value of similar used equipment currently available for sale.

Accrued Payroll and Employee Liabilities and Other Accrued Expense

Accrued payroll and employee liabilities and other accrued expense consisted of the following (in thousands):

	December 31,
	2014		2013
Accrued employee salaries and benefits	$	719	$	796
Accrued bonuses		2,012		1,770
Total accrued payroll and employee liabilities	$	2,731	$	2,566

	December 31,
	2014		2013
Accrued professional fees	$	1,775	$	69
Accrued accounts payable		886		26
Deferred rent		105		131
Other accrued liabilities		165		138
Total other accrued expense	$	2,931	$	364

Note 5 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

5.	Commitments and Contingencies

Leases

We lease 26,067 square feet of laboratory, office and warehouse space in Redwood City, California under a lease expiring on November 30, 2016. In addition, we currently lease 1,400 square feet of office space in Stamford, Connecticut and 2,020 square feet of office space in San Diego, California. The lease for the Connecticut office space was extended in 2014 for a three-month period ending on March 31, 2015. The lease for the San Diego office space was extended in 2014 for a six-month period ending on June 30, 2015. We believe our facilities are adequate and suitable for our current needs, and we will be able to obtain new or additional leased space in the future when necessary. We also lease certain office equipment under operating lease arrangements.

Annual future minimum lease payments as of December 31, 2014 are as follows (in thousands):

	Operating Leases
Years ended December 31,
2015	$	867
2016		722
2017		—
2018		—
2019		—
Thereafter		—
Total	$	1,589

Rent expense under all operating leases totaled approximately $1,381,000, $967,000 and $580,000 for the years ended December 31, 2014, 2013 and 2012, respectively.

Clinical Development Agreements

We have entered into agreements with various vendors for the research and development of product candidates, which are generally cancellable anytime at our option. Under the terms of these agreements, the vendors provide a variety of services including conducting preclinical development, research, manufacturing clinical compounds, enrolling and recruiting patients, monitoring studies, data analysis and regulatory filing assistance. Payments under these agreements typically include fees for services and reimbursement of expenses. In addition, under certain agreements, we are subject to penalties in the event we permanently discontinue performance under these agreements.

Purchase Obligations

At December 31, 2014, purchase obligations of approximately $877,000 primarily consisted of commitments with third-party manufacturers of materials to be used in our clinical and pre-clinical studies, as well as commitments with various vendors for clinical and preclinical studies. Approximately $218,000 of the total purchase obligations were not included in our financial statements for the year ended December 31, 2014.

Note 6 - Senior Secured Convertible Notes to Related Parties

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

6.	Senior Secured Convertible Notes to Related Parties

In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5 million in Convertible Notes. We received a total of $4.3 million, net of issuance costs, from the issuance of these Convertible Notes.

The Convertible Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Convertible Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Convertible Notes, at the election of the purchasers. The Convertible Notes mature on May 2, 2021, however, the holders of the Convertible Notes may require prepayment of the Convertible Notes at any time, at each holder’s option.

The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes. There is no right to convert the Convertible Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Convertible Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.

As of December 31, 2014, we were in compliance with all covenants under the Convertible Notes. Upon the occurrence of an event of default under the Convertible Notes, the holders of the Convertible Notes have the right to require us to redeem all or a portion of their Convertible Notes.

We filed a registration statement with the Securities and Exchange Commission (“SEC”) to register for resale 3.5 million shares underlying the Convertible Notes. The registration statement was declared effective on July 29, 2011. The Note holders have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Convertible Notes until they provide notice otherwise.

The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a debt discount was recorded in an amount equal to the face value of the Convertible Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Convertible Notes. During the year ended December 31, 2014, accrued interest of approximately $309,000 was paid-in-kind and rolled into the Note principal balance, which resulted in an additional debt discount of approximately $309,000. For the year ended December 31, 2014, 2013 and 2012, interest expense relating to the stated rate was approximately $314,000, $295,000 and $216,000, respectively, and interest expense relating to the amortization of the debt discount was approximately $573,000, $533,000 and $389,000, respectively.

As of December 31, 2014, the carrying value of the Convertible Notes was approximately $1,598,000, which is comprised of the $5,341,000 principal amount of the Convertible Notes outstanding, less debt discount of $3,743,000. If the $5,341,000 principal amount of Convertible Notes is converted, we would issue 6,676,845 shares of our common stock.

Note 7 - Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

7. Stockholders’ Equity

Amendments to Articles of Incorporation – Reverse Stock Split

Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1 - for - 20 reverse split of our outstanding common stock. The name change and Reverse Stock Split were approved by our stockholders on September 19, 2013. As a result of the Reverse Stock Split, we amended our Certificate of Incorporation to reduce the total authorized shares of our common stock from 1,500,000,000 to 75,000,000 shares.

2011 Private Placement

In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July 1, 2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.

On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (“Rule 144”). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise.

During the year ended December 31, 2014, warrant holders exercised 460,706 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 303,614 shares of common stock and no net cash proceeds to us. During the year ended December 31, 2013, we received $0.6 million for cash exercises of these warrants. During the year ended December 31, 2012, warrant holders exercised 7,500 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 5,034 shares of common stock and no net cash proceeds to us.

2012 Private Placement

In July 2012, we sold approximately 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1 million in issuance costs). On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012.

2013 Common Stock Offering

In November 2013, we sold approximately 7.7 million shares of our common stock at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9 million in issuance costs). The offering was made pursuant to an effective registration statement, which was previously filed with the SEC and was declared effective.

2014 Common Stock Offering

In June 2014, we sold approximately 4.8 million shares of our common stock at a public offering price of $11.75 per share. In addition, as a component of the offering, we sold 600,000 pre-funded warrants to purchase shares of our common stock at a public offering price of $11.74 per share. The pre-funded warrants have an exercise price of $0.01 per share and are exercisable for seven years from the date of issuance. We received total net proceeds of approximately $58.9 million (net of approximately $4.0 million in issuance costs) from the sale of the common stock and the pre-funded warrants. The offering was made pursuant to an effective registration statement, which was previously filed with the SEC and was declared effective.

Common Stock Reserved for Future Issuance

Shares of Company common stock reserved for future issuance at December 31, 2014 were as follows:

	Number of Shares
Stock options outstanding		7,918,004
Stock options available for grant		1,333,212
Employee stock purchase plan		29,893
Warrants outstanding		4,108,147
Common stock underlying Convertible Notes outstanding		6,676,845
Total shares reserved for future issuance		20,066,101

Warrants

The following table summarizes the warrants outstanding as of December 31, 2014:

	Number of Shares Outstanding		Exercise Price		Expiration Date
Issued to private placement investors in October 2009		198,860	$	17.60	01/07/2015
Issued to private placement investors in July 2011		3,289,287	$	3.60	07/01/2016
Issued in a public offering in June 2014		600,000	$	0.01	06/30/2021
Other		20,000	$	13.80	08/01/2015
Total warrants outstanding		4,108,147

The weighted-average exercise price of warrants outstanding as of December 31, 2014 was $3.80.

Employee Stock Purchase Plan

In 1997 our stockholders approved our Employee Stock Purchase Plan (the “ESPP”). In December 2007, May 2009, June 2011 and May 2014, our stockholders authorized increases in the number of shares reserved for issuance under the ESPP by 5,000, 10,000, 25,000 and 25,000 shares, respectively, for a total of 75,000 shares reserved at December 31, 2014. Under the terms of the ESPP, employees can elect to have up to a maximum of 10% of their base earnings withheld to purchase our common stock. The purchase price of the stock is 85% of the lower of the closing prices for our common stock on: (i) the first trading day in the enrollment period, as defined in the ESPP, in which the purchase is made, or (ii) the purchase date. The length of the enrollment period is six months. Enrollment dates are the first business day of May and November and the first enrollment date was April 30, 1997. Approximately 24% of eligible employees participated in the ESPP in 2014. Under the ESPP, we issued 12,028, 5,630 and 4,270 shares in 2014, 2013 and 2012, respectively. The weighted-average exercise price per share of the purchase rights exercised during 2014, 2013 and 2012 was $7.59, $6.12 and $5.21, respectively. As of December 31, 2014, 45,107 shares of common stock have been issued under the ESPP and 29,893 shares of common stock are available for future issuance.

Stock Option Plans

We currently have one stock option plan from which we can grant options and restricted stock awards to employees, officers, directors and consultants. In December 2007, the stockholders approved our 2007 Equity Incentive Plan (the “2007 Plan”) at which time a maximum of 150,000 shares of common stock were available for grant. In May 2010, June 2011 and May 2014, our stockholders approved amendments to our 2007 Plan to increase the maximum number of shares of common stock available for grant by 100,000, 4,500,000 and 1,750,000 shares of common stock, respectively, resulting in an aggregate of 6,500,000 shares of common stock authorized for issuance as of December 31, 2014. At December 31, 2014, there were 1,333,212 shares available for future grant under the 2007 Plan. Any shares that are issuable upon exercise of options granted that expire, are cancelled, or are received back by us pursuant to a net exercise of options, are available for future grant and issuance.

We also granted stock options and restricted stock awards under the 2002 Stock Incentive Plan (the “2002 Plan”) in prior years. The remaining shares available to be granted under the 2002 Plan expired in February 2012.

In 2014, 2013 and 2012, we granted options to certain employees outside of our stockholder approved stock option plans. All options to purchase our common stock were granted with an exercise price which equals fair market value of the underlying common stock on the grant dates and expire no later than ten years from the date of grant. The options are exercisable in accordance with vesting schedules that generally provide for them to be fully vested and exercisable four years after the date of grant, provided, however, that we have also issued stock options awards that are subject to performance vesting requirements. All stock option grants issued outside of our stockholder approved plans have been registered on Form S-8 with the SEC.

A summary of our stock option activity and related data follows:

	Outstanding Options
				Weighted-
				Average
	Number of			Exercise
	Shares			Price
Balance at December 31, 2011		2,505,283		$	6.13
Granted		1,874,246			11.61
Exercised		—			—
Cancelled		(55,655	)		9.56
Balance at December 31, 2012		4,323,874			8.46
Granted		4,256,971			8.08
Exercised		(537,029	)		5.20
Cancelled		(1,688,135	)		9.45
Balance at December 31, 2013		6,355,681			8.22
Granted		3,181,001			9.40
Exercised		(756,593	)		6.34
Cancelled		(862,085	)		9.88
Balance at December 31, 2014		7,918,004		$	8.69

For the year ended December 31, 2014, option holders exercised 756,593 stock options, a portion of which were exercised under the cashless exercise provision of the 2007 Plan, resulting in the net issuance of 587,997 shares of common stock and cash proceeds to us of approximately $3.1 million.

For the year ended December 31, 2014, options cancelled (included in the above table) consisted of 806,507 options forfeited with a weighted-average exercise price of approximately $9.06 and 55,578 options expired with a weighted-average exercise price of approximately $21.64.

As of December 31, 2014, options exercisable have a weighted-average remaining contractual term of 6.3 years. The total intrinsic value of stock option exercises, which is the difference between the exercise price and closing price of our common stock on the date of exercise, during the years ended December 31, 2014 and 2013, was approximately $3,377,000 and $1,720,000, respectively. There were no exercises during the year ended December 31, 2012. As of December 31, 2014 and 2013, the total intrinsic value of options outstanding and exercisable was approximately $14,654,000 and $4,943,000, respectively, which is the difference between the exercise price and closing price of our common stock.

	Years Ended December 31,
	2014				2013				2012
			Weighted-				Weighted-				Weighted-
			Average				Average				Average
			Exercise				Exercise				Exercise
	Options		Price		Options		Price		Options		Price
Exercisable at end of year		2,237,901	$	9.01		1,770,597	$	8.67		1,142,099	$	7.98
Options vested or expected to vest		7,841,074	$	8.69		6,292,296	$	8.22		4,283,344	$	8.45

Exercise prices and weighted-average remaining contractual lives for the options outstanding as of December 31, 2014 were:

									Weighted-
			Weighted-						Average
			Average		Weighted-				Exercise
			Remaining		Average				Price of
Options		Range of	Contractual		Exercise		Options		Options
Outstanding		Exercise Prices	Life (in years)		Price		Exercisable		Exercisable
	953,090	$3.80 – $7.00		5.92	$	5.78		662,840	$	5.34
	2,511,808	$7.20		8.01		7.20		531,578		7.20
	2,428,458	$7.61 – $9.05		9.12		8.87		204,669		8.95
	1,991,338	$9.20 – $15.40		7.42		11.27		805,504		12.09
	33,310	$15.41 – $139.20		1.05		36.97		33,310		36.97
	7,918,004	$3.80 – $139.20		7.92		8.69		2,237,901		9.01

At December 31, 2014, we had reserved 7,918,004 shares of common stock for future issuance upon exercise of outstanding options granted under the 2002 and 2007 Plans, as well as the non-plan grants.

Valuation and Expense Information

The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements for the years ended December 31, 2014, 2013 and 2012 (in thousands):

	December 31,
	2014		2013		2012
Research and development	$	3,329	$	2,562	$	1,617
General and administrative		4,738		8,328		4,115
Stock-based compensation expense included in operating expenses	$	8,067	$	10,890	$	5,732

As of December 31, 2014, there was $34,073,000 of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a weighted-average period of 2.6 years.

For the years ended December 31, 2014, 2013, and 2012, we estimated the fair value of each option grant and ESPP purchase right on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

Options:

	December 31,
	2014			2013			2012
Risk-free interest rate		1.9	%		1.1	%		0.8	%
Dividend yield		—	%		—	%		—	%
Volatility		99.0	%		104.2	%		106.2	%
Expected life (years)		6.0			6.0			5.5

ESPP:

	December 31,
	2014			2013			2012
Risk-free interest rate		0.1	%		0.1	%		0.2	%
Dividend yield		—	%		—	%		—	%
Volatility		53.8	%		76.0	%		77.9	%
Expected life (years)		0.5			0.5			0.5

The weighted-average fair value of options granted was $7.40, $6.53 and $9.21 for the years ended December 31, 2014, 2013 and 2012, respectively.

The weighted-average fair value of shares purchased through the ESPP was $3.06, $3.01 and $4.00 for the years ended December 31, 2014, 2013 and 2012, respectively.

The risk-free interest rate assumption is based on observed interest rates on United States Treasury debt securities with maturities close to the expected term of our employee and director stock options and ESPP purchases.

The dividend yield assumption is based on our history and expectation of dividend payouts. We have never paid dividends on its common stock and we do not anticipate paying dividends in the foreseeable future.

We used our historical stock price to estimate volatility.

The expected life of employee and director stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. We have elected to use the simplified method, as we do not have enough historical exercise experience to provide a reasonable basis upon which to estimate the expected term. The expected life for the ESPP purchase rights is six months, which represents the length of each purchase period.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 8 - Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

8.	Income Taxes

For the years ended December 31, 2014, 2013 and 2012, we did not record a provision for income taxes because we have incurred operating losses for all three years.

Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation allowance at year-end are as follows (in thousands):

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carryforward	$	59,513		$	31,834
Research and development credits		7,667			4,792
Stock-based compensation		5,128			4,124
Other, net		964			487
Total deferred tax assets		73,272			41,237
Valuation allowance for net deferred tax assets		(73,272	)		(41,237	)
Net deferred taxes	$	—		$	—

Taxes on income vary from the statutory federal income tax rate applied to earnings before tax on income as follows (in thousands):

	December 31,
	2014			2013			2012
Statutory federal income tax rate of 34%	$	(25,965	)	$	(18,796	)	$	(7,937	)
Stock-based compensation expense		551			513			176
NOL not benefitted		25,085			17,983			7,551
Other, net		329			300			210
Provision for taxes	$	—		$	—		$	—

A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized. We have established a valuation allowance to offset net deferred tax assets at December 31, 2014, and 2013 due to the uncertainty of realizing future tax benefits from our net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended December 31, 2014 and 2013 was an increase of approximately $32,035,000 and $22,038,000, respectively.

At December 31, 2014, we had federal and California state net operating loss carryforwards of approximately $149,573,000 and $148,402,000, respectively, expiring beginning in 2018 for federal and 2015 for California state purposes. At December 31, 2014, we had federal and California state research credit carryforwards of approximately $4,676,000 and $4,493,000, respectively, expiring beginning in 2022 for federal. The California state credits can be carried forward indefinitely.

Internal Revenue Code section 382 places a limitation on the amount of taxable income that can be offset by net operating (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 limitation. We have performed an IRC Section 382 analysis and determined there were ownership changes in 2007, 2011, and 2013. There may be further ownership changes after December 31, 2014. The limitation in the Federal and state carryforwards associated with the NOL and credit carryforwards reduce the deferred tax assets, which are further offset by a full valuation allowance. The limitation can result in the expiration of the NOLs and credit carryforwards available as of December 31, 2014 before utilization.

We adopted the ASC Topic 740 provisions regarding Uncertainty in Income Taxes as of January 1, 2009. For benefits to be realized, a tax position must be more likely than not to be sustained upon examination. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement.

As of December 31, 2014, we had unrecognized tax benefits of $120,000, and the amount that would impact our effective tax rate, before the consideration of the valuation allowance, is $120,000.

It is our policy to recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2014, we had no accrued interest and penalties related to uncertain tax positions.

We file U.S. and state income tax returns with varying statutes of limitations. The tax years from 1997 to 2014 remain open to examination due to the carryover of unused net operating losses and tax credits.

We do not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next 12 months.

	December 31,
	2014		2013
	(in thousands)
Unrecognized tax benefit:
Beginning of period	$	120	$	120
Current year changes		—		—
Prior year changes		—		—
End of Period	$	120	$	120

Note 9 - Employee Benefit Plan

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

9.	Employee Benefit Plan

We have a defined contribution 401K plan (the “Plan”) covering substantially all of our employees. In the past three calendar years, we made matching cash contributions equal to 50% of each participant’s contribution during the Plan year up to a maximum amount equal to the lesser of 3% of each participant’s annual compensation or $7,800, $7,650 and $7,500 for the years 2014, 2013 and 2012, respectively. Such amounts were recorded as expense in the corresponding years. We may also contribute additional discretionary amounts to the Plan as we may determine. For the years ended December 31, 2014, 2013 and 2012, we contributed to the Plan approximately $181,000, $134,000 and $71,000, respectively. No discretionary contributions have been made to the Plan since its inception.

Note 10 - Discontinued Operations

12 Months Ended

Dec. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

10.	Discontinued Operations

For the year ended December 31, 2012, we recognized a gain from discontinued operations of approximately $1.1 million related to the reversal of a gross profit guaranty from our sale of certain technology in 2000.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Note 11 - Summary of Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

11.	Summary of Quarterly Financial Data (unaudited)

The following is a summary of the unaudited quarterly results of operations for the years ended December 31, 2014 and 2013:

	2014
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Operating expenses:
Research and development	$	11,628		$	14,279		$	14,731		$	14,195
General and administrative		5,694			4,512			4,222			5,300
Loss from operations		(17,322	)		(18,791	)		(18,953	)		(19,495	)
Interest income		—			—			—			3
Interest expense		(216	)		(220	)		(224	)		(227	)
Other expense		—			—			(17	)		(905	)
Net loss	$	(17,538	)	$	(19,011	)	$	(19,194	)	$	(20,624	)
Basis and diluted net loss per share	$	(0.74	)	$	(0.78	)	$	(0.66	)	$	(0.71	)

	2013
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Operating expenses:
Research and development	$	7,065		$	10,748		$	6,165		$	8,538
General and administrative		5,687			4,461			6,500			5,293
Loss from operations		(12,752	)		(15,209	)		(12,665	)		(13,831	)
Interest income		1			1			—			—
Interest expense		(202	)		(205	)		(209	)		(212	)
Other expense		—			—			—			—
Net loss	$	(12,953	)	$	(15,413	)	$	(12,874	)	$	(14,043	)
Basis and diluted net loss per share	$	(0.85	)	$	(1.01	)	$	(0.84	)	$	(0.75	)

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain amounts in the 2013 financial statements have been reclassified to conform to the 2014 presentation.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Fair Value Measurement, Policy [Policy Text Block]

Fair Value of Financial Instruments

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Clinical Trial Accruals [Policy Text Block]

Accrued Clinical Liabilities

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Legal Costs, Policy [Policy Text Block]

Patent Costs

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation Expense

Warrants Issued in Equity Financings [Policy Text Block]

Warrants

Income Tax, Policy [Policy Text Block]

Income Taxes

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (Loss)

Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

	As of December 31,
	2014		2013		2012

Stock options outstanding		7,918		6,356		4,324
Warrants outstanding		4,108		3,969		4,219
Common stock underlying Convertible Notes outstanding		6,677		6,291		5,927

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of December 31,
	2014		2013		2012

Stock options outstanding		7,918		6,356		4,324
Warrants outstanding		4,108		3,969		4,219
Common stock underlying Convertible Notes outstanding		6,677		6,291		5,927

Note 4 - Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure Text Block Supplement [Abstract]

Property, Plant and Equipment [Table Text Block]

	December 31,
	2014			2013
Scientific equipment	$	4,793		$	4,371
Computer equipment and software		1,133			1,080
Furniture, fixtures and office equipment		351			344
Leasehold improvements		1,376			1,360
		7,653			7,155
Less: accumulated depreciation and amortization		(4,833	)		(4,273	)
	$	2,820		$	2,882

Schedule of Accrued Liabilities [Table Text Block]

	December 31,
	2014		2013
Accrued employee salaries and benefits	$	719	$	796
Accrued bonuses		2,012		1,770
Total accrued payroll and employee liabilities	$	2,731	$	2,566

	December 31,
	2014		2013
Accrued professional fees	$	1,775	$	69
Accrued accounts payable		886		26
Deferred rent		105		131
Other accrued liabilities		165		138
Total other accrued expense	$	2,931	$	364

Note 5 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

	Operating Leases
Years ended December 31,
2015	$	867
2016		722
2017		—
2018		—
2019		—
Thereafter		—
Total	$	1,589

Note 7 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders' Equity Note [Abstract]

Common Stock Reserved for Future Issuance [Table Text Block]

	Number of Shares
Stock options outstanding		7,918,004
Stock options available for grant		1,333,212
Employee stock purchase plan		29,893
Warrants outstanding		4,108,147
Common stock underlying Convertible Notes outstanding		6,676,845
Total shares reserved for future issuance		20,066,101

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Shares Outstanding		Exercise Price		Expiration Date
Issued to private placement investors in October 2009		198,860	$	17.60	01/07/2015
Issued to private placement investors in July 2011		3,289,287	$	3.60	07/01/2016
Issued in a public offering in June 2014		600,000	$	0.01	06/30/2021
Other		20,000	$	13.80	08/01/2015
Total warrants outstanding		4,108,147

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Outstanding Options
				Weighted-
				Average
	Number of			Exercise
	Shares			Price
Balance at December 31, 2011		2,505,283		$	6.13
Granted		1,874,246			11.61
Exercised		—			—
Cancelled		(55,655	)		9.56
Balance at December 31, 2012		4,323,874			8.46
Granted		4,256,971			8.08
Exercised		(537,029	)		5.20
Cancelled		(1,688,135	)		9.45
Balance at December 31, 2013		6,355,681			8.22
Granted		3,181,001			9.40
Exercised		(756,593	)		6.34
Cancelled		(862,085	)		9.88
Balance at December 31, 2014		7,918,004		$	8.69

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]

	Years Ended December 31,
	2014				2013				2012
			Weighted-				Weighted-				Weighted-
			Average				Average				Average
			Exercise				Exercise				Exercise
	Options		Price		Options		Price		Options		Price
Exercisable at end of year		2,237,901	$	9.01		1,770,597	$	8.67		1,142,099	$	7.98
Options vested or expected to vest		7,841,074	$	8.69		6,292,296	$	8.22		4,283,344	$	8.45

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

									Weighted-
			Weighted-						Average
			Average		Weighted-				Exercise
			Remaining		Average				Price of
Options		Range of	Contractual		Exercise		Options		Options
Outstanding		Exercise Prices	Life (in years)		Price		Exercisable		Exercisable
	953,090	$3.80 – $7.00		5.92	$	5.78		662,840	$	5.34
	2,511,808	$7.20		8.01		7.20		531,578		7.20
	2,428,458	$7.61 – $9.05		9.12		8.87		204,669		8.95
	1,991,338	$9.20 – $15.40		7.42		11.27		805,504		12.09
	33,310	$15.41 – $139.20		1.05		36.97		33,310		36.97
	7,918,004	$3.80 – $139.20		7.92		8.69		2,237,901		9.01

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	December 31,
	2014		2013		2012
Research and development	$	3,329	$	2,562	$	1,617
General and administrative		4,738		8,328		4,115
Stock-based compensation expense included in operating expenses	$	8,067	$	10,890	$	5,732

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	December 31,
	2014			2013			2012
Risk-free interest rate		1.9	%		1.1	%		0.8	%
Dividend yield		—	%		—	%		—	%
Volatility		99.0	%		104.2	%		106.2	%
Expected life (years)		6.0			6.0			5.5

	December 31,
	2014			2013			2012
Risk-free interest rate		0.1	%		0.1	%		0.2	%
Dividend yield		—	%		—	%		—	%
Volatility		53.8	%		76.0	%		77.9	%
Expected life (years)		0.5			0.5			0.5

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Note 8 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31,
	2014			2013
Deferred tax assets:
Net operating loss carryforward	$	59,513		$	31,834
Research and development credits		7,667			4,792
Stock-based compensation		5,128			4,124
Other, net		964			487
Total deferred tax assets		73,272			41,237
Valuation allowance for net deferred tax assets		(73,272	)		(41,237	)
Net deferred taxes	$	—		$	—

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	December 31,
	2014			2013			2012
Statutory federal income tax rate of 34%	$	(25,965	)	$	(18,796	)	$	(7,937	)
Stock-based compensation expense		551			513			176
NOL not benefitted		25,085			17,983			7,551
Other, net		329			300			210
Provision for taxes	$	—		$	—		$	—

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	December 31,
	2014		2013
	(in thousands)
Unrecognized tax benefit:
Beginning of period	$	120	$	120
Current year changes		—		—
Prior year changes		—		—
End of Period	$	120	$	120

Note 11 - Summary of Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

	2014
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Operating expenses:
Research and development	$	11,628		$	14,279		$	14,731		$	14,195
General and administrative		5,694			4,512			4,222			5,300
Loss from operations		(17,322	)		(18,791	)		(18,953	)		(19,495	)
Interest income		—			—			—			3
Interest expense		(216	)		(220	)		(224	)		(227	)
Other expense		—			—			(17	)		(905	)
Net loss	$	(17,538	)	$	(19,011	)	$	(19,194	)	$	(20,624	)
Basis and diluted net loss per share	$	(0.74	)	$	(0.78	)	$	(0.66	)	$	(0.71	)

	2013
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(In thousands, except per share amounts)
Operating expenses:
Research and development	$	7,065		$	10,748		$	6,165		$	8,538
General and administrative		5,687			4,461			6,500			5,293
Loss from operations		(12,752	)		(15,209	)		(12,665	)		(13,831	)
Interest income		1			1			—			—
Interest expense		(202	)		(205	)		(209	)		(212	)
Other expense		—			—			—			—
Net loss	$	(12,953	)	$	(15,413	)	$	(12,874	)	$	(14,043	)
Basis and diluted net loss per share	$	(0.85	)	$	(1.01	)	$	(0.84	)	$	(0.75	)

Note 1 - Organization and Business (Details) - USD ($) $ in Thousands	48 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure Text Block [Abstract]
Retained Earnings (Accumulated Deficit)	$ (315,237)	$ (238,870)
Proceeds from Issuance of Long-term Debt and Capital Securities, Net	194,300
Cash	$ 72,700

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	5 years
Unrecognized Tax Benefits	$ 120,000	$ 120,000	$ 120,000

Note 2 - Summary of Significant Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share - shares shares in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	7,918	6,356	4,324
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	4,108	3,969	4,219
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded	6,677	6,291	5,927

Note 4 - Balance Sheet Details (Details) - USD ($)	12 Months Ended
Note 4 - Balance Sheet Details (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equipment [Member]
Note 4 - Balance Sheet Details (Details) [Line Items]
Asset Impairment Charges	$ 905,000
Assets Held-for-sale, Long Lived, Fair Value Disclosure	115,000
Depreciation	578,000	$ 333,000	$ 197,000
Asset Impairment Charges	$ 905,000

Note 4 - Balance Sheet Details (Details) - Property and Equipment - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,793	$ 4,371
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,133	1,080
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	351	344
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,376	1,360
Property and equipment, gross	7,653	7,155
Less: accumulated depreciation and amortization	(4,833)	(4,273)
	$ 2,820	$ 2,882

Note 4 - Balance Sheet Details (Details) - Acrued Expenses - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Acrued Expenses [Abstract]
Accrued employee salaries and benefits	$ 719	$ 796
Accrued bonuses	2,012	1,770
Total accrued payroll and employee liabilities	2,731	2,566
Accrued professional fees	1,775	69
Accrued accounts payable	886	26
Deferred rent	105	131
Other accrued liabilities	165	138
Total other accrued expense	$ 2,931	$ 364

Note 5 - Commitments and Contingencies (Details)	12 Months Ended
Note 5 - Commitments and Contingencies (Details)	Dec. 31, 2014 USD ($) ft²	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Redwood City [Member]
Note 5 - Commitments and Contingencies (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²	26,067
Stamford [Member]
Note 5 - Commitments and Contingencies (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²	1,400
San Diego [Member]
Note 5 - Commitments and Contingencies (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²	2,020
Operating Leases, Rent Expense \| $	$ 1,381,000	$ 967,000	$ 580,000
Purchase Obligation \| $	877,000
Unrecorded Unconditional Purchase Obligation \| $	$ 218,000

Note 5 - Commitments and Contingencies (Details) - Future Minimum Lease Payments $ in Thousands	Dec. 31, 2014 USD ($)
Future Minimum Lease Payments [Abstract]
2015	$ 867
2016	722
Total	$ 1,589

Note 6 - Senior Secured Convertible Notes to Related Parties (Details)		1 Months Ended	12 Months Ended
	Jul. 29, 2011 shares	Apr. 30, 2011 USD ($) shares	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
In Case of Debt Conversion [Member] \| Convertible Debt Securities [Member]
Note 6 - Senior Secured Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument, Face Amount			$ 5,341,000
Debt Instrument, Convertible, Number of Equity Instruments			6,676,845
Common Stock [Member] \| Convertible Debt Securities [Member]
Note 6 - Senior Secured Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument Conversion Ratio, Shares (in Shares) \| shares		1,250
Convertible Debt Securities [Member]
Note 6 - Senior Secured Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Maturity Date		May 02, 2021
Debt Instrument Conversion Ratio, Multiple of Principal		$ 1,000
Beneficial Ownership After Conversion		9.99%
Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes		61 days
Paid-in-Kind Interest			$ 309,000
Debt Instrument, Increase (Decrease), Other, Net			309,000
Carrying Value of Notes Outstanding			1,598,000
Debt Instrument, Face Amount			5,341,000
Debt Instrument, Unamortized Discount			3,743,000
Convertible Debt Issuable In Connection With Private Placement1		$ 4,500,000
Proceeds from Convertible Debt		$ 4,300,000			$ 3,000,000
Common Shares Registered For Resale In Connection With Convertible Notes (in Shares) \| shares	3,500,000
Interest Expense, Debt, Excluding Amortization			314,000	$ 295,000	216,000
Amortization of Debt Discount (Premium)			573,000	533,000	$ 389,000
Carrying Value of Notes Outstanding			$ 1,598,000	$ 1,025,000

Note 7 - Stockholders' Equity (Details)		1 Months Ended								12 Months Ended			25 Months Ended
Note 7 - Stockholders' Equity (Details)	Jan. 13, 2014	Jun. 30, 2014 USD ($) $ / shares shares	May 31, 2014 shares	Nov. 30, 2013 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Jun. 30, 2011 USD ($) $ / shares shares	May 31, 2010 shares	May 31, 2009 shares	Dec. 31, 2007 shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Jun. 30, 2013	Sep. 13, 2013 shares	Sep. 12, 2013 shares
Private Placement 2011 [Member] \| Common Stock [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Common Stock (in Dollars) \| $										$ 0
Pre Funded Warrants [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares		$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		600,000
Share Price (in Dollars per share) \| $ / shares		$ 11.74
Warrant Term		7 years
Private Placement 2011 [Member] \| Common Stock [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						8,000,000				303,614
Stock Issued During Period, Value, New Issues (in Dollars) \| $						$ 22,800,000
Payments of Stock Issuance Costs (in Dollars) \| $						$ 1,200,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						0.5
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised												5,034
Private Placement 2011 [Member] \| Warrant [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised										460,706		7,500
Private Placement 2011 [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares						$ 3.60
Limitation On Exercisable Warrants													9.99%
Proceeds from Warrant Exercises (in Dollars) \| $										$ 600,000
Private Placement 2012 [Member] \| Common Stock [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					5,100,000
Stock Issued During Period, Value, New Issues (in Dollars) \| $					$ 50,500,000
Payments of Stock Issuance Costs (in Dollars) \| $					$ 3,100,000
Private Placement 2012 [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) \| $ / shares					$ 10.50
Common Stock [Member] \| Equity Incentive Plan 2007 [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net										587,997
Common Stock [Member] \| Jefferies LLC [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				7,700,000
Payments of Stock Issuance Costs (in Dollars) \| $				$ 3,900,000
Proceeds from Issuance of Common Stock (in Dollars) \| $				$ 57,800,000
Sale of Stock, Price Per Share (in Dollars per share) \| $ / shares				$ 8.00
Common Stock [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		4,800,000
Sale of Stock, Price Per Share (in Dollars per share) \| $ / shares		$ 11.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										588,000	537,000
Common Stock and Prefunded Warrants [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Payments of Stock Issuance Costs (in Dollars) \| $		$ 4,000,000
Proceeds from Issuance or Sale of Equity (in Dollars) \| $		$ 58,900,000
Reverse Stock Split [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Weighted Average [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) \| $ / shares										$ 3.80
Employee Stock Purchase Plan [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized						25,000		10,000	5,000	25,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										75,000
Maximum Base Earnings Withheld										10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount on Stock Purchase Price										85.00%
Percent of Eligible Employees										24.00%
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period										12,028	5,630	4,270
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) \| $ / shares										$ 7.59	$ 6.12	$ 5.21
Common Stock, Shares, Issued										45,107
Common Stock, Capital Shares Reserved for Future Issuance										29,893
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) \| $ / shares										$ 7.40	6.53	9.21
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Fair Value Price of Shares Purchased (in Dollars per share) \| $ / shares										$ 3.06	$ 3.01	$ 4.00
Equity Incentive Plan 2007 [Member]
Note 7 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			1,750,000			4,500,000	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									150,000	6,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										1,333,212
Proceeds from Stock Options Exercised (in Dollars) \| $										$ 3,100,000
Common Stock, Shares Authorized										75,000,000	75,000,000			75,000,000	1,500,000,000
Proceeds from Issuance of Common Stock (in Dollars) \| $										$ 58,916,000	$ 57,802,000	$ 50,491,000
Proceeds from Warrant Exercises (in Dollars) \| $											$ 600,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										4,108,147
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) \| $ / shares										$ 6.34	$ 5.20
Common Stock, Shares, Issued										29,227,000	23,572,000
Common Stock, Capital Shares Reserved for Future Issuance										20,066,101
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										1,333,212
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										756,593	537,029	0
Proceeds from Stock Options Exercised (in Dollars) \| $										$ 3,101,000	$ 2,793,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period										806,507
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in Dollars per share) \| $ / shares										$ 9.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period										55,578
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in Dollars per share) \| $ / shares										$ 21.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term										6 years 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars) \| $										$ 3,377,000	1,720,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars) \| $										$ 14,654,000	$ 4,943,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options										7,918,004
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars) \| $										$ 34,073,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										2 years 219 days

Note 7 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance - shares	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Common Stock Reserved for Future Issuance [Abstract]
Stock options outstanding	7,918,004	6,355,681	4,323,874	2,505,283
Stock options available for grant	1,333,212
Employee stock purchase plan	29,893
Warrants outstanding	4,108,147
Common stock underlying Convertible Notes outstanding	6,676,845
Total shares reserved for future issuance	20,066,101

Note 7 - Stockholders' Equity (Details) - Warrants Outstanding	Dec. 31, 2014 $ / shares shares
Private Placement, October 2009 [Member]
Class of Warrant or Right [Line Items]
Number of shares outstanding	198,860
Exercise price (in Dollars per share) \| $ / shares	$ 17.60
Private Placement, July 2011 [Member]
Class of Warrant or Right [Line Items]
Number of shares outstanding	3,289,287
Exercise price (in Dollars per share) \| $ / shares	$ 3.60
Public Offering, June 2014 [Member]
Class of Warrant or Right [Line Items]
Number of shares outstanding	600,000
Exercise price (in Dollars per share) \| $ / shares	$ 0.01
Other Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares outstanding	20,000
Exercise price (in Dollars per share) \| $ / shares	$ 13.80
Number of shares outstanding	4,108,147

Note 7 - Stockholders' Equity (Details) - Option Summary - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Option Summary [Abstract]
Number of shares	7,918,004	6,355,681	4,323,874
Weighted-average exercise price	$ 8.69	$ 8.22	$ 8.46
Weighted-average exercise price, granted	$ 9.40	$ 8.08	$ 11.61
Number of shares, granted	3,181,001	4,256,971	1,874,246
Number of shares, exercised	(756,593)	(537,029)	0
Weighted-average exercise price, exercised	$ 6.34	$ 5.20
Number of shares, cancelled	(862,085)	(1,688,135)	(55,655)
Weighted-average exercise price, cancelled	$ 9.88	$ 9.45	$ 9.56

Note 7 - Stockholders' Equity (Details) - Options Exercisable, Vested or Expected to Vest. - $ / shares	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Options Exercisable, Vested or Expected to Vest. [Abstract]
Exercisable at end of year	2,237,901	1,770,597	1,142,099
Exercisable at end of year	$ 9.01	$ 8.67	$ 7.98
Options vested or expected to vest	7,841,074	6,292,296	4,283,344
Options vested or expected to vest	$ 8.69	$ 8.22	$ 8.45

Note 7 - Stockholders' Equity (Details) - Exercise Price Ranges	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Price Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	953,090
Lower exercise price	$ 3.80
Exercise price	5.34
Upper exercise price	$ 7.00
Weighted-average remaining contractual life, outstanding	5 years 335 days
Weighted-average exercise price	$ 5.78
Options exercisable (in Shares) \| shares	662,840
Weighted-average exercise price of options exercisable	$ 5.34
Price Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	2,511,808
Exercise price	$ 7.20
Weighted-average remaining contractual life, outstanding	8 years 3 days
Weighted-average exercise price	$ 7.20
Options exercisable (in Shares) \| shares	531,578
Weighted-average exercise price of options exercisable	$ 7.20
Price Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	2,428,458
Lower exercise price	$ 7.61
Exercise price	8.95
Upper exercise price	$ 9.05
Weighted-average remaining contractual life, outstanding	9 years 43 days
Weighted-average exercise price	$ 8.87
Options exercisable (in Shares) \| shares	204,669
Weighted-average exercise price of options exercisable	$ 8.95
Price Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	1,991,338
Lower exercise price	$ 9.20
Exercise price	12.09
Upper exercise price	$ 15.40
Weighted-average remaining contractual life, outstanding	7 years 153 days
Weighted-average exercise price	$ 11.27
Options exercisable (in Shares) \| shares	805,504
Weighted-average exercise price of options exercisable	$ 12.09
Price Range 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	33,310
Lower exercise price	$ 15.41
Exercise price	36.97
Upper exercise price	$ 139.20
Weighted-average remaining contractual life, outstanding	1 year 18 days
Weighted-average exercise price	$ 36.97
Options exercisable (in Shares) \| shares	33,310
Weighted-average exercise price of options exercisable	$ 36.97
Price Range 6 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding (in Shares) \| shares	7,918,004
Lower exercise price	$ 3.80
Exercise price	9.01
Upper exercise price	$ 139.20
Weighted-average remaining contractual life, outstanding	7 years 335 days
Weighted-average exercise price	$ 8.69
Options exercisable (in Shares) \| shares	2,237,901
Weighted-average exercise price of options exercisable	$ 9.01
Options outstanding (in Shares) \| shares	7,918,004

Note 7 - Stockholders' Equity (Details) - Allocation of the Recognized Cost - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 3,329	$ 2,562	$ 1,617
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	4,738	8,328	4,115
Stock-based compensation expense	$ 8,067	$ 10,890	$ 5,732

Note 7 - Stockholders' Equity (Details) - Option Valuation Assumptions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]
Note 7 - Stockholders' Equity (Details) - Option Valuation Assumptions [Line Items]
Risk-free interest rate	1.90%	1.10%	0.80%
Volatility	99.00%	104.20%	106.20%
Expected life (years)	6 years	6 years	5 years 6 months
Employee Stock Purchase Plan [Member]
Note 7 - Stockholders' Equity (Details) - Option Valuation Assumptions [Line Items]
Risk-free interest rate	0.10%	0.10%	0.20%
Volatility	53.80%	76.00%	77.90%
Expected life (years)	6 months	6 months	6 months

Note 8 - Income Taxes (Details) - USD ($)	12 Months Ended
Note 8 - Income Taxes (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Domestic Tax Authority [Member]
Note 8 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$ 149,573,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	4,676,000
State and Local Jurisdiction [Member]
Note 8 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	148,402,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	4,493,000
Income Tax Expense (Benefit)	0	$ 0	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	32,035,000	22,038,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	7,667,000	4,792,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	120,000
Unrecognized Tax Benefits	$ 120,000	$ 120,000	$ 120,000

Note 8 - Income Taxes (Details) - Components of Defered Tax Assets - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$ 59,513	$ 31,834
Research and development credits	7,667	4,792
Stock-based compensation	5,128	4,124
Other, net	964	487
Total deferred tax assets	73,272	41,237
Valuation allowance for net deferred tax assets	(73,272)	(41,237)
Net deferred taxes	$ 0	$ 0

Note 8 - Income Taxes (Details) - Provisions - USD ($)	12 Months Ended
Note 8 - Income Taxes (Details) - Provisions - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Provisions [Abstract]
Statutory federal income tax rate of 34%	$ (25,965,000)	$ (18,796,000)	$ (7,937,000)
Stock-based compensation expense	551,000	513,000	176,000
NOL not benefitted	25,085,000	17,983,000	7,551,000
Other, net	329,000	300,000	210,000
Provision for taxes	$ 0	$ 0	$ 0

Note 8 - Income Taxes (Details) - Provisions (Parentheticals)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Provisions [Abstract]
Statutory federal income tax rate	34.00%	34.00%	34.00%

Note 8 - Income Taxes (Details) - Reconciliation of Unrecognized Tax Benefits - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Unrecognized tax benefit:
Beginning of period	$ 120,000	$ 120,000
Current year changes	0	0
Prior year changes	0	0
End of Period	$ 120,000	$ 120,000

Note 9 - Employee Benefit Plan (Details) - USD ($)	12 Months Ended
Note 9 - Employee Benefit Plan (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Maximum [Member]
Note 9 - Employee Benefit Plan (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%	3.00%	3.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%	50.00%	50.00%
Defined Contribution Plan, Maximum Annual Contributions by Employer, Per Employee, Amount	$ 7,800	$ 7,650	$ 7,500
Defined Contribution Plan, Cost Recognized	181,000	$ 134,000	$ 71,000
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 10 - Discontinued Operations (Details) $ in Thousands	12 Months Ended
Note 10 - Discontinued Operations (Details) $ in Thousands	Dec. 31, 2012 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ 1,082

Note 11 - Summary of Quarterly Financial Data (Unaudited) (Details) - Quarterly Results of Operations - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating expenses:
Research and development	$ 14,195	$ 14,731	$ 14,279	$ 11,628	$ 8,538	$ 6,165	$ 10,748	$ 7,065	$ 54,833	$ 32,516	$ 15,174
General and administrative	5,300	4,222	4,512	5,694	5,293	6,500	4,461	5,687	19,728	21,941	8,657
Loss from operations	(19,495)	(18,953)	(18,791)	(17,322)	(13,831)	(12,665)	(15,209)	(12,752)	(76,367)	(55,283)	(24,430)
Interest income	3						1	1
Interest expense	(227)	(224)	(220)	(216)	(212)	(209)	(205)	(202)	(887)	(828)	(605)
Other expense	(905)	(17)							(919)	2	6
Net loss	$ (20,624)	$ (19,194)	$ (19,011)	$ (17,538)	$ (14,043)	$ (12,874)	$ (15,413)	$ (12,953)	$ (76,367)	$ (55,283)	$ (23,348)
Basis and diluted net loss per share (in Dollars per share)	$ (0.71)	$ (0.66)	$ (0.78)	$ (0.74)	$ (0.75)	$ (0.84)	$ (1.01)	$ (0.85)	$ (2.87)	$ (3.42)	$ (1.91)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Label	Element	Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 6.13